ES2187530T3 - Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b. - Google Patents

Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.

Info

Publication number
ES2187530T3
ES2187530T3 ES94925160T ES94925160T ES2187530T3 ES 2187530 T3 ES2187530 T3 ES 2187530T3 ES 94925160 T ES94925160 T ES 94925160T ES 94925160 T ES94925160 T ES 94925160T ES 2187530 T3 ES2187530 T3 ES 2187530T3
Authority
ES
Spain
Prior art keywords
peptides
viruses
ctitotoxy
hepatitis
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925160T
Other languages
English (en)
Inventor
Francis V Chisari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2187530T3 publication Critical patent/ES2187530T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE UTILIZAN PEPTIDOS PARA DEFINIR EPITOPOS QUE SIMULAN LA ACTIVIDAD CITOTOXICA DE LOS LINFOCITOS T CONTRA ANTIGENOS DEL VIRUS DE LA HEPATITIS B. LOS PEPTIDOS SE DERIVAN DE REGIONES DE POLIMERASA DEL HBV, Y SON PARTICULARMENTE UTILES EN EL TRATAMIENTO O LA PREVENCION DE INFECCIONES POR EL HBV, INCLUYENDO METODOS PARA ESTIMULAR LA RESPUESTA INMUNE DE INDIVIDUOS CRONICAMENTE INFECTADOS PARA QUE RESPONDAN A LOS ANTIGENOS DEL HBV.
ES94925160T 1993-08-02 1994-08-01 Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b. Expired - Lifetime ES2187530T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10087093A 1993-08-02 1993-08-02

Publications (1)

Publication Number Publication Date
ES2187530T3 true ES2187530T3 (es) 2003-06-16

Family

ID=22281958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94925160T Expired - Lifetime ES2187530T3 (es) 1993-08-02 1994-08-01 Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.

Country Status (11)

Country Link
EP (1) EP0726758B1 (es)
JP (2) JP3650110B2 (es)
AT (1) ATE227118T1 (es)
AU (1) AU702367B2 (es)
CA (1) CA2168583C (es)
DE (1) DE69431665T2 (es)
DK (1) DK0726758T3 (es)
ES (1) ES2187530T3 (es)
NZ (1) NZ271531A (es)
PT (1) PT726758E (es)
WO (1) WO1995003777A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
JP2001504799A (ja) * 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
EP1049711B1 (en) * 1998-01-19 2003-12-10 Mogam Biotechnology Research Institute Liposomes comprising peptide antigens derived from x protein of hepatitis b virus
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
JP2004517609A (ja) * 2000-09-01 2004-06-17 エピミューン インコーポレイテッド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
EP2187937A1 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2015187009A1 (en) * 2014-06-02 2015-12-10 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
KR20230030032A (ko) 2016-06-20 2023-03-03 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
AU2017372731B2 (en) 2016-12-05 2024-05-23 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
KR20200101416A (ko) * 2017-12-19 2020-08-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(hbv) 백신 및 그 용도
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EP3740245A4 (en) 2018-01-19 2022-01-05 Janssen Pharmaceuticals, Inc. INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS
KR102234027B1 (ko) * 2018-05-09 2021-03-31 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드 및 이의 항바이러스 용도
WO2023009770A1 (en) * 2021-07-30 2023-02-02 Tevogen Bio, Inc. Methods for developing cd3+cd8+ cells against multiple viral epitopes for treatment of viral infections including variants evolving to escape previous immunity
CN114478711A (zh) * 2022-01-05 2022-05-13 成都朗谷生物科技股份有限公司 一种针对乙型肝炎病毒的抗原肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244102A (en) * 1991-08-26 1996-12-20 Scripps Research Inst Peptides inducing cytotoxic t lymphocyte responses against hbv antigen and their use
EP1704868A1 (en) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA binding peptides and their uses
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição

Also Published As

Publication number Publication date
EP0726758B1 (en) 2002-11-06
DE69431665T2 (de) 2003-08-21
CA2168583A1 (en) 1995-02-09
DE69431665D1 (de) 2002-12-12
CA2168583C (en) 2007-10-02
EP0726758A4 (en) 1997-01-29
WO1995003777A1 (en) 1995-02-09
JPH09501165A (ja) 1997-02-04
DK0726758T3 (da) 2003-03-03
AU7518494A (en) 1995-02-28
NZ271531A (en) 1998-02-26
ATE227118T1 (de) 2002-11-15
JP2005170926A (ja) 2005-06-30
PT726758E (pt) 2003-03-31
AU702367B2 (en) 1999-02-18
JP3650110B2 (ja) 2005-05-18
EP0726758A1 (en) 1996-08-21

Similar Documents

Publication Publication Date Title
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DK0534618T3 (da) Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus
ES2155060T3 (es) Epitopos del virus de la hepatitis b incluidos en la respuesta de los linfocitos t citotoxicos (ctl) restringida para hla.
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
DE59003895D1 (de) Arbeitszange.
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
MX9101810A (es) Vacuna contra virus de anemia de polio y diagnostico
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
DE69902103T2 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
DK720588D0 (da) Forbindelser til anvendelse ved behandling eller forebyggelse af human-immundefektvirus-(hiv)-infektion, og farmaceutiske praeparater indeholdende samme
DE69428112T2 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
ES2042481T1 (es) Peptidos sinteticos que derivan del antigeno hbc del virus de la hepatitis b.
MX9201711A (es) Metodo para retardar y reducir la aparicion del virus resistente a analogos de nucleosidos, en un paciente que tiene una infeccion por vih.
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
MY157594A (en) Compositions of matter useful in the treatment of viral infections derived from plant extracts